Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

241. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study

The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study Lamy A, Jonsson B, Weintraub W S, Zhao F, Chrolavicius S, Bakhai A, Culler S, Gafni A, Lindgren P, Mahoney E, Yusuf S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of clopidogrel, compared with placebo, in the treatment of acute coronary syndromes (ACS). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

NHS Economic Evaluation Database.2004

242. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) coronary syndromes: a systematic review and economic evaluation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST

Health Technology Assessment (HTA) Database.2004

244. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. 14724302 2004 01 15 2004 01 22 2013 11 21 1533-4406 350 3 2004 Jan 15 The New England journal of medicine N. Engl. J. Med. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. 232-8 Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after (...) pretreatment with clopidogrel is unknown. We enrolled 2159 patients with coronary artery disease who underwent a percutaneous coronary intervention: 1079 patients were randomly assigned in a double-blind manner to receive abciximab and 1080 patients to receive placebo. All patients were pretreated with a 600-mg dose of clopidogrel at least two hours before the procedure. The primary end point of the trial was the composite of death, myocardial infarction, and urgent target-vessel revascularization within

NEJM2004

245. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis

Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis Casella G, Ottani F, Pavesi P C, Sangiorgio P, Rubboli A, Galvani M, Fontanelli A, Bracchetti D CRD summary This review concluded (...) that clopidogrel plus aspirin was more effective and had a better safety profile than ticlodipine plus aspirin in patients who had undergone coronary stenting. The review has a number of methodological limitations, which mean that the conclusions cannot be relied upon. Authors' objectives To determine the efficacy and safety of clopidogrel plus aspirin compared with ticlodipine plus aspirin after coronary stenting. Searching MEDLINE was searched until December 2001 for papers written in English; some

DARE.2003

246. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial

Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial Annemans L, Lamotte M, Levy E, Lenne X Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of clopidogrel, an antiplatelet agent, in patients with atherothrombosis. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with vascular disease with recent stroke, myocardial

NHS Economic Evaluation Database.2003

247. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. BACKGROUND: Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary heart disease. We estimated the cost effectiveness of the increased use of aspirin, clopidogrel, or both for secondary prevention in patients with coronary heart disease. METHODS: We used the Coronary Heart Disease Policy Model, a computer simulation of the U.S. population, to estimate (...) the incremental cost effectiveness (in dollars per quality-adjusted years of life gained) of four strategies in patients over 35 years of age with coronary disease from 2003 to 2027: aspirin for all eligible patients (i.e., those who were not allergic to or intolerant of aspirin), aspirin for all eligible patients plus clopidogrel for patients who were ineligible for aspirin, clopidogrel for all patients, and the combination of aspirin for all eligible patients plus clopidogrel for all patients. RESULTS

NEJM2002

248. Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel?

Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Abdulwadud O Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Abdulwadud O. Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 10 Authors' objectives This aim of this critical appraisal was to assess whether cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel. Project page URL Indexing Status Subject indexing

Health Technology Assessment (HTA) Database.2002

249. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial.

The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. Boucher M (...) , Armstrong P, Pharand C, Skidmore B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boucher M, Armstrong P, Pharand C, Skidmore B. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. Ottawa: Canadian Coordinating Office for Health

Health Technology Assessment (HTA) Database.2002

250. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease Gaspoz J-M, Coxson P G, Goldman P A, Williams L W, Kuntz K M, Hunnink M, Goldman L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of aspirin and clopidogrel (a thienopyridine derivative) for secondary prevention in patients with coronary heart disease (CHD). Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised patients over 35

NHS Economic Evaluation Database.2002

253. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 11519503 2001 08 16 2001 08 30 2013 11 21 0028-4793 345 7 2001 Aug 16 The New England journal of medicine N. Engl. J. Med. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 494-502 Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major (...) vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients. We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months. The first primary outcome--a composite of death from cardiovascular causes, nonfatal myocardial infarction

NEJM2001

254. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. 11520521 2001 08 24 2001 09 20 2015 06 16 0140-6736 358 9281 2001 Aug 18 Lancet (London, England) Lancet Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. 527-33 Despite the use of aspirin, there is still a risk of ischaemic (...) events after percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI. 2658 patients with non-ST-elevation acute coronary syndrome undergoing PCI in the CURE study had been randomly assigned double-blind treatment with clopidogrel (n=1313) or placebo (n=1345). Patients were pretreated with aspirin

Lancet2001

255. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis

Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost (...) -effectiveness analysis Shah H, Gondek K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of antiplatelet therapy for the prevention of recurrent ischaemic stroke was studied. The antiplatelet agents considered were clopidogrel (75

NHS Economic Evaluation Database.2000

256. Antiplatelet agents – clopidogrel (Plavix)

Antiplatelet agents – clopidogrel (Plavix) Antiplatelet agents – clopidogrel (Plavix) We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Antiplatelet agents – clopidogrel (Plavix) Share: Reading time approx. 2 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert (...) This is a translation of version 1, published on October 29, 1999. The latest version of this report is not available in English. Clopidogrel is a recently approved drug which helps prevent the formation of blood clots in vascular diseases resulting from atherosclerosis. There is strong evidence that drugs which inhibit blood clots, eg, acetylsalicylic acid (ASA), have prophylactic effects in patients with atherosclerotic disease. The effects of clopidogrel have been compared to the effects of ASA in a randomized

Swedish Council on Technology Assessement2000

257. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. BACKGROUND: The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin. Aspirin inhibits platelet activation by inhibiting platelet cyclooxygenase and thromboxane production, and reduces the odds of a serious vascular event by about (...) a quarter. The thienopyridines (ticlopidine and clopidogrel) inhibit platelet activation by a different mechanism to aspirin (blocking the ADP receptor on platelets), and so may be more effective than aspirin. OBJECTIVES: The objective of this review was to determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for the prevention of serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk

Cochrane2000

258. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. 8918275 1996 12 17 1996 12 17 2015 06 16 0140-6736 348 9038 1996 Nov 16 Lancet (London, England) Lancet A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. 1329-39 Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk (...) of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic

Lancet1996